Expression of metallothionein [MT] and glutathione s-transferase pi [SGTP] in the bone marrow of patients with myeloproliferative disorders [MPD]

• Autorzy: Wrobel T , Mazur G. , Dziegiel P. , Surowiak P. , Kuliczkowski K. , Zabel M.
• Języki publikacji: EN

Abstrakty

EN

Overexpression of SGTP and/or MT may contribute to various carcinogenic processes and to resistance to anticancer treatment. The importance of these proteins, although clearly established in solid tumours, has not been fully understood in haematopoietic neoplasm. The aim of this study was to determine the expression of MT and SGTP in the bone marrow of patients with MPD. Twenty paraffin-embedded bone marrow core biopsy specimens from newly diagnosed patients with MPD were evaluated — osteomyelofibrosis (OMF), n = 9 and chronic myelocytic leukaemia (CML), n = 11. We demonstrate increased SGTP and MT expression in the bone marrow of MPD patients. In our study levels of MT in OMF patients were higher than in CML. This suggests that MT expression may correlate with bone marrow fibrosis. These data, although based on a relatively small number of patients, raise the possibility that SGTP and MT may play a role in the pathogenesis of MPD. The clinical significance of this phenomenon needs further investigation.

Słowa kluczowe

EN

glutathione s-transferase; anticancer treatment; bone marrow; metallothionein; myeloproliferative disorder

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2004
• Tom: 63
• Numer: 1
• Opis fizyczny: p.129-131,fig.,ref.

Twórcy

autor

Wrobel T

• Medical University, Pasteura 4, 50-367 Wroclaw, Poland

autor

Mazur G.

autor

Dziegiel P.

autor

Surowiak P.

autor

Kuliczkowski K.

autor

Zabel M.

Bibliografia

• 1. Berendsen ChL, Mulder TP, Peters WHM (2000) Plasma gluthatione s-transferase pi 1-1 and alfa 1-1 levels in patients with bladder cancer. J Urol, 164: 2126–2128.
• 2. Court E, Smith M, Avent N, Hancock J, Morgan L, Gray A, Smith J (2003) cDNA microarray screening of constitutive gene expression in bone marrow samples from norma, non-AML, AML patients and AML cell lines. Br J Haematol, 121 (Suppl): 74.
• 3. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzock R, Kantarijan HM (1999) The biology of chronic myeloid leukemia. N Engl J Med, 341: 164–172.
• 4. Ioachim E, Goussia A, Agnantis N, Machera M, Tsianos E, Kappas A (1999) Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J Clin Pathol, 52: 876–879.
• 5. Saga Y, Hashimoto H, Yachiku S, Tokumisu M, Kaneko S (2002) Immunohistochemical expression of metallothionein in human bladder cancer: correlation with histopathological parameters and patients survival. J Urol, 168: 2227–2231.
• 6. Sauerbrey A, Zintl F, Hermann J, Volm M (1998) Multiple resistance mechanism in acute nonlymphoblastic leukemia (ANLL). Anticancer Res, 18: 1231–1236.
• 7. Tefferi A (1998) The Philadelphia chromosome negative chronic myeloproliferative disorders: A practical overview. Mayo Clin Proc, 73: 1177–1184.
• 8. Tsabouri S, Georgiou I, Alamanos I, Bourantas K (2000) Increased prevalence of GSTM (1) null genotype in patients with myelodysplastic syndrome: a case-control study. Acta Haematol, 104: 169–173.
• 9. Vasak M, Hasler DW (2000) Metallothioneins: new functional and structural insights. Curr Opin Chem Biol, 4: 177–183.
• 10. Vlachogeorgos GS, Manali E, Mermigis D, Blana E, Legaki S, Karagiannidis N, Mermighis C, Polychronopoulos V (2001) The role of expression of gluthatione s transferase pi (GST-pi) and p-glycoprotein (p-gp) in cytologic specimen in the outcome of patients with lung cancer. Chest, 120 (Suppl): 315S.